Its hard to not also wonder whether the sluggish launch of Roctavian and the broader ups and downs for BioMarin over recent years made it logical to move on to a successor sooner versus later Still BioMarin said sales are ramping up better than expected for its Voxzogo therapy for a condition called achondroplasia that affects bone growth